S. Becker

发表

Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.

N. Graham, S. Raffanti, K. Henry, 2001, AIDS research and human retroviruses.

Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced with an Anti-Tat Ribozyme in a Multi-Center, Randomized, Placebo-Controlled, Phase II Gene Therapy Trial for the Human Immunodeficiency Virus

C. von Kalle, T. Merigan, M. Winters, 2009, Nature Medicine.

Erratum: Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection (AIDS (2000) 14 (671-681))

J. Tolson, J. Eron, P. Ruane, 2000 .

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers

J. Park, C. Flexner, C. Hendrix, 2008, Antimicrobial Agents and Chemotherapy.

Meeting reportPlanning for pre-exposure prophylaxis to prevent HIV transmission : challenges and opportunities

M. Dybul, J. Mellors, P. Piot, 2018 .

Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.

L. Chinn, J. Gow, D. Kroetz, 2007, The Journal of antimicrobial chemotherapy.

New targets, new drugs, failed trials and the need for more information.

S. Becker, 2004, Positively aware : the monthly journal of the Test Positive Aware Network.

Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers

M. Nyunt, C. Hendrix, G. Calandra, 2008, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

J. Cummins, A. Kashuba, J. Turpin, 2013, AIDS research and human retroviruses.

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial

C. Duncombe, C. Feldman, A. Vos, 2018, Journal of acquired immune deficiency syndromes.

Treatment as prevention: translating efficacy trial results to population effectiveness.

G. Garnett, S. Bertozzi, S. Becker, 2012, Current opinion in HIV and AIDS.

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa

M. Sculpher, T. Hallett, S. Lewin, 2016, The Journal of infectious diseases.

Liver toxicity in epidemiological cohorts.

S. Becker, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study.

J. Feinberg, G. Fusco, S. Becker, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.

V. Johnson, M. Saag, E. Acosta, 2019, AIDS research and human retroviruses.

CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

P. Anderson, T. Kakuda, S. Becker, 2004, AIDS.

Human immunodeficiency virus type-1 Vpu inhibitor, BIT225, in combination with 3-drug antiretroviral therapy modulates inflammation and immune cells functions.

R. Murphy, S. Gatechompol, A. Avihingsanon, 2020, The Journal of infectious diseases.

Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort

N. Hansen, N. Graham, G. Slatko, 2001, Journal of acquired immune deficiency syndromes.

Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Peter B Gilbert, Max Essex, James O Berger, 2011, The Journal of infectious diseases.

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Christof von Kalle, Roger Garsia, Robert Finlayson, 2009, Nature medicine.

Fosamprenavir: advancing HIV protease inhibitor treatment options

S. Becker, L. Thornton, 2004, Expert Opinion on Pharmacotherapy.

Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus

J. Benner, E. Hazard, J. Munakata, 2006, Medical care.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.

N. Hansen, A. Justice, B. Sherrill, 2004, Journal of clinical epidemiology.

Pharmacokinetics of Saquinavir With Atazanavir or Low‐Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers

E. Acosta, T. Kakuda, J. King, 2007, Journal of clinical pharmacology.

Atazanavir: improving the HIV protease inhibitor class

S. Becker, 2003, Expert review of anti-infective therapy.

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

M. King, B. Bernstein, G. Hanna, 2007, The Journal of antimicrobial chemotherapy.

ANAPHYLACTOID DRUG REACTIONS TO CIPROFLOXACIN AND RIFAMPICIN IN HIV-INFECTED PATIENTS

M. Maß, D. Abrams, R. Wurtz, 1989, The Lancet.

Implications of HIV PrEP trials results.

V. DeGruttola, C. Fletcher, D. Burns, 2011, AIDS research and human retroviruses.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection

J. Tolson, J. Eron, P. Ruane, 2000, AIDS.

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

S. Becker, 2003, Expert opinion on investigational drugs.

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

M. Dybul, J. Mellors, P. Piot, 2010, Journal of the International AIDS Society.

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents

A. Owen, M. Boffito, A. Jackson, 2013, Drugs.

Young HIV-infected adults are at greater risk for medication nonadherence.

Hugh Kawabata, Stephen L Becker, Christopher M Dezii, 2002, MedGenMed : Medscape general medicine.

Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.

N. Hansen, N. Graham, G. Slatko, 2001 .

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.

R. Haubrich, C. Flexner, S. Piscitelli, 2001, Journal of acquired immune deficiency syndromes.

reportPlanning for pre-exposure prophylaxis to prevent HIV transmission : challenges and opportunities

M. Dybul, J. Mellors, P. Piot, 2010 .

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

Edwin DeJesus, M. Boffito, R. Wong, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

J. Park, C. Flexner, C. Hendrix, 2007, Antimicrobial Agents and Chemotherapy.

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR 4 Antagonist AMD 070 in Healthy Volunteers †

J. Park, C. Flexner, C. Hendrix, 2008 .

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers (cid:1) †

J. Park, C. Flexner, C. Hendrix, 2008 .

A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults

Gary Richmond, Edwin DeJesus, Richard Haubrich, 2002, Antiviral therapy.